| A case report of treatment with pegylated interferon alpha for Lamivudine-resistant chronic hepatitis B virus infection |
| Won Haing Hur , Hyun Young Woo , Soung Won Jeong , Chan Ran You , Si Hyun Bae , Jong Young Choi , Seung Kew Yoon |
| Department of Internal Medicine, College of Medicine, The Catholic University of Korea, WHO Collaborating Center of Viral Hepatitis, Seoul, Korea |
|
|
|
|
|
| ABSTRACT |
|
|
The wide use of lamivudine in chronic hepatitis B has produced a monotonic increase in patients with lamivudine resistance. Therefore, treating lamivudine resistance in chronic hepatitis B is a major concern in clinical practice for the treatment of hepatitis B virus (HBV). There is conflicting evidence on the outcome of pegylated interferon alpha (PEG-IFN α) therapy against lamivudine-resistant HBV, which is due to mutations in the YMDD motif. We experienced a patient with chronic hepatitis B who was successfully treated with PEG-IFN α-2a after the development of virologic and biochemical breakthrough during lamivudine therapy. Virologic breakthrough was associated with the emergence of YMDD mutants 48 months after starting lamivudine therapy. Treatment with PEG-IFN α-2a for 12 months resulted in an undetectable serum level of HBV DNA and the resolution of hepatitis, and the virologic response was maintained over 16 months after cessation of PEG-IFN α-2a. (Korean J Hepatol 2008;14:513-518) |
| KeyWords:
Pegylated interferon alfa-2a; Lamivudine; YMDD motif mutant; Hepatitis B, Chronic |
|
|
PDF Links
Full text via DOI
Download Citation
